NCT00369161View on ClinicalTrials.gov

A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients

PHASE4CompletedINTERVENTIONAL
Enrollment

228

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Renal Transplantation
Interventions
DRUG

Everolimus (RAD001)

DRUG

Tacrolimus

DRUG

Basiliximab

DRUG

Corticosteroids

Trial Locations (1)

Unknown

Novartis, Basel

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00369161 - A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients | Biotech Hunter | Biotech Hunter